Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest

Cancer Immunology Research

Volumn 3, Issue 1, 2015, Pages 37-47

  Acquavella, Nicolas ^a,i   Clever, David ^a   Yu, Zhiya ^a   Roelke Parker, Melody ^b   Palmer, Douglas C ^a   Xi, Liqiang ^a   Pflicke, Holger ^a   Ji, Yun ^a   Gros, Alena ^a   Hanada, Ken Ichi ^a   Goldlust, Ian S ^c,d   Mehta, Gautam U ^a   Klebanoff, Christopher A ^a   Crompton, Joseph G ^a,d   Sukumar, Madhusudhanan ^a   Morrow, James J ^e   Franco, Zulmarie ^a,j   Gattinoni, Luca ^a   Liu, Hui ^b   Wang, Ena ^g   Marincola, Francesco ^g   Stroncek, David F ^f   Lee, Chyi Chia R ^a   Raffeld, Mark ^a   Bosenberg, Marcus W ^h   Roychoudhuri, Rahul ^a   Restifo, Nicholas P ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

^h YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF MIAMI   (United States)

^j CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA; VEMURAFENIB; CYTOKINE; INDOLE DERIVATIVE; SULFONAMIDE;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL VIABILITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG POTENTIATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA B16; MELANOMA CELL LINE; MOUSE; NONHUMAN; S PHASE CELL CYCLE CHECKPOINT; SENSITIZATION; TUMOR GROWTH; UPREGULATION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; C57BL MOUSE; DISEASE COURSE; DISEASE MODEL; GENETICS; IMMUNOLOGY; MELANOMA; MUTATION; NEOPLASM METASTASIS; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOKINES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INDOLES; MELANOMA; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS B-RAF; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 84962320363     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-14-0122     Document Type: Article

References (50)

1. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
2. Fecher LA, Amaravadi RK, Flaherty KT. The MAPK pathway in melanoma. Curr Opin Oncol 2008;20:183-9.
3. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
4. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, openlabel, phase 3 randomised controlled trial. Lancet 2012;380:358-65.
5. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-14.
6. Rosenberg SA Cell transfer immunotherapy for metastatic solid cancer - what clinicians need to know. Nat Rev Clin Oncol 2011;8:577-85.
7. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011;17:4550-7.
8. Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res 2013; 19:393-403.
9. Koya RC, Mok S, Otte N, Blacketor KJ, Comin-Anduix B, Tumeh PC, et al. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res 2012;72:3928-37.
10. Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF, et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 2012;18:1386-94.
11. Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013;19: 1225-31.
12. Knight DA, Ngiow SF, Li M, Parmenter T, Mok S, Cass A, et al. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest 2013;123:1371-81.
13. Ho PC, Meeth KM, Tsui YC, Srivastava B, Bosenberg MW, Kaech SM. Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγamma. Cancer Res 2014;74:3205-17.
14. Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010;70:5213-9.
15. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 1998; 95:7556-61.
16. Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1994;1:447-56.
17. Braumuller H, Wieder T, Brenner E, Assmann S, Hahn M, Alkhaled M, et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 2013; 494:361-5.
18. + T cells. J Exp Med 2003; 198:569-80.
19. Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev 2007;21:379-84.
20. Bosenberg M, Muthusamy V, Curley DP, Wang Z, Hobbs C, Nelson B, et al. Characterization of melanocyte-specific inducible Cre recombinase transgenic mice. Genesis 2006;44:262-7.
21. Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, et al. Pten dose dictates cancer progression in the prostate. PLoS Biol 2003;1:E59.
22. Harada N, Tamai Y, Ishikawa T, Sauer B, Takaku K, Oshima M, et al. Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. EMBO J 1999;18:5931-42.
23. Gartner JJ, Davis S, Wei X, Lin JC, Trivedi NS, Teer JK, et al. Comparative exome sequencing of metastatic lesions provides insights into the mutational progression of melanoma. BMC Genomics 2012;13:505.
24. Loewe S, Muischnek H. Effect of combinations: mathematical basis of problem. Arch Exp Pathol Pharmacol 1926;114:313-26.
25. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE Jr, et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 2009;41:544-52.
26. Damsky WE, Curley DP, Santhanakrishnan M, Rosenbaum LE, Platt JT, Gould Rothberg BE, et al. beta-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell 2011;20: 741-54.
27. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, et al. Dissecting therapeutic resistanceto RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011;29:3085-96.
28. Chin YE, Kitagawa M, Su WC, You ZH, Iwamoto Y, Fu XY. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science 1996;272:719-22.
29. Bromberg JF, Horvath CM, Wen Z, Schreiber RD, Darnell JE Jr Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc Natl Acad Sci U S A 1996;93:7673-8.
30. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001; 84:1424-31.
31. Merlino G, Flaherty K, Acquavella N, Day CP, Aplin A, Holmen S, et al. Meeting report: the future of preclinical mouse models in melanoma treatment is now. Pigment Cell Melanoma Res 2013;26:E8-E14.
32. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, et al. A landscape of driver mutations in melanoma. Cell 2013;150: 251-63.
33. Cooper ZA, Juneja VR, Sage PT, Frederick DT, Piris A, Mitra D, et al. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res 2014;2: 643-54.
34. Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, et al. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov 2014;11:873-86.
35. Comin-Anduix B, Chodon T, Sazegar H, Matsunaga D, Mock S, Jalil J, et al. The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res 2012;16:6040-8.
36. Hong DS, Vence L, Falchook G, Radvanyi LG, Liu C, Goodman V, et al. BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res 2010;18:2326-35.
37. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007;445:851-7.
38. Detjen KM, Farwig K, Welzel M, Wiedenmann B, Rosewicz S. Interferon gamma inhibits growth of human pancreatic carcinoma cells via caspase-1 dependent induction of apoptosis. Gut 2001;49:251-62.
39. Chin YE, Kitagawa M, Kuida K, Flavell RA, Fu XY. Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Mol Cell Biol 1997;17:5328-37.
40. Listopad JJ, Kammertoens T, Anders K, Silkenstedt B, Willimsky G, Schmidt K, et al. Fas expression by tumor stroma is required for cancer eradication. Proc Natl Acad Sci U S A 2013;110:2276-81.
41. Byrd JC, O'Brien S, James DF. Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369:1278-9.
42. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013;369:507-16.
43. Neffendorf JE, Gout I, Hildebrand GD. Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369:1277.
44. Rushworth SA, MacEwan DJ, Bowles KM. Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369:1277-8.
45. Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med 2014;370:2286-94.
46. Furman RR, Cheng S, Lu P, Setty M, Perez AR, Guo A, et al. Ibrutinib resistance in chronic lymphocytic leukemia. N Engl J Med 2014;370: 2352-4.
47. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptormodified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365:725-33.
48. Kochenderfer JN, Rosenberg SA. Chimeric antigen receptor-modified T cells in CLL. N Engl J Med 2011;365:1937-8.
49. Pardoll DM The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
50. Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013; 368:1365-6.